Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,970,000 shares, an increase of 9.7% from the December 31st total of 3,620,000 shares. Based on an average trading volume of 598,100 shares, the days-to-cover ratio is currently 6.6 days. Currently, 4.3% of the company's shares are short sold.
赛特克生物科学公司(纳斯达克代码：CTKB-GET Rating)在一月份见证了空头股数的大幅增长。截至1月15日，空头股数共有397万股，比12月31日的362万股增加了9.7%。以598,100股的平均成交量计算，目前天数与回补比率为6.6天。目前，该公司4.3%的股票被卖空。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, Piper Sandler increased their target price on Cytek Biosciences from $16.00 to $18.00 in a research note on Monday, November 14th.
另外，派珀·桑德勒在11月14日周一的一份研究报告中将Cytek Biosciences的目标价从16.00美元上调至18.00美元。
Insider Activity
内幕活动
In other news, Director Jack Ball sold 16,000 shares of the company's stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $14.69, for a total value of $235,040.00. Following the completion of the sale, the director now directly owns 3,000 shares of the company's stock, valued at approximately $44,070. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Patrik Jeanmonod sold 3,500 shares of the company's stock in a transaction dated Tuesday, January 24th. The stock was sold at an average price of $11.05, for a total value of $38,675.00. Following the completion of the sale, the chief financial officer now directly owns 76,132 shares of the company's stock, valued at approximately $841,258.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Ball sold 16,000 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $14.69, for a total value of $235,040.00. Following the sale, the director now directly owns 3,000 shares of the company's stock, valued at $44,070. The disclosure for this sale can be found here. Insiders sold a total of 146,500 shares of company stock valued at $1,824,960 in the last ninety days. 15.90% of the stock is owned by insiders.
在其他新闻方面，董事杰克球在一笔日期为11月14日星期一的交易中出售了16,000股该公司股票。该股以14.69美元的平均价格出售，总价值为235,040.00美元。出售完成后，董事现在直接持有该公司3000股股票，价值约44,070美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。在其他新闻方面，首席财务官Patrik Jeanmonod在1月24日星期二的交易中出售了3500股公司股票。这只股票的平均售价为11.05美元，总价值为38,675.00美元。出售完成后，首席财务官现在直接拥有76,132股公司股票，价值约841,258.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。此外，在11月14日(星期一)的一次交易中，董事杰克球出售了16,000股该股。该股以14.69美元的平均价格出售，总价值为235,040.00美元。交易完成后，董事现在直接持有该公司3000股股票，价值44,070美元。关于这次销售的披露可以找到这里。在过去的90天里，内部人士总共抛售了146,500股公司股票，价值1,824,960美元。15.90%的股份由内部人士持有。
Institutional Investors Weigh In On Cytek Biosciences
机构投资者看好赛特克生物科学公司
Cytek Biosciences Stock Performance
赛特克生物科学公司股票表现
NASDAQ CTKB traded up $0.43 during trading hours on Tuesday, reaching $12.14. 286,762 shares of the company's stock were exchanged, compared to its average volume of 706,353. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -1,194.00 and a beta of 0.06. Cytek Biosciences has a one year low of $7.38 and a one year high of $16.05. The company's 50-day moving average is $11.39 and its two-hundred day moving average is $12.99.
在周二的交易时段，新浪纳斯达克的股价上涨了0.43美元，达到12.14美元。该公司股票成交量为286,762股，而其平均成交量为706,353股。该公司市值为16.4亿美元，市盈率为-1194.00，贝塔系数为0.06。Cytek Biosciences的一年低点为7.38美元，一年高位为16.05美元。该公司50日移动均线切入位在11.39美元，200日移动均线切入位在12.99美元。
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). The business had revenue of $40.48 million for the quarter, compared to the consensus estimate of $43.36 million. Cytek Biosciences had a positive return on equity of 0.94% and a negative net margin of 0.47%. Research analysts predict that Cytek Biosciences will post 0.04 earnings per share for the current fiscal year.
赛特克生物科学公司(纳斯达克代码：CTKB-GET Rating)最近一次发布季度收益报告是在11月9日星期三。该公司公布本季度每股收益为0.01美元，低于普遍预期的0.02美元(0.01美元)。该业务本季度的收入为4,048万美元，而普遍预期为4,336万美元。Cytek Biosciences的股本回报率为正0.94%，净利润率为负0.47%。研究分析师预测，Cytek Biosciences本财年的每股收益将为0.04美元。
About Cytek Biosciences
关于赛特克生物科学公司
(Get Rating)
(获取评级)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家细胞分析解决方案公司，提供细胞分析工具，促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统，这是一种光谱流动细胞仪，通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析；以及极光细胞分选系统，它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- Verizon，Charge在过去的一个月里趋势更高：他们现在购买吗？
- 股利之王Sysco：逢低买入
- 天才集团股票1600%的涨幅合理吗？
- 在进一步审查后，投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖出另一个收购机会吗？
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。